8,345 Shares in Cencora, Inc. (NYSE:COR) Acquired by Vega Investment Solutions

by · The Cerbat Gem

Vega Investment Solutions bought a new position in Cencora, Inc. (NYSE:COR – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund bought 8,345 shares of the company’s stock, valued at approximately $1,875,000. Cencora accounts for approximately 1.5% of Vega Investment Solutions’ investment portfolio, making the stock its 15th largest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. JFS Wealth Advisors LLC grew its position in Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock worth $27,000 after purchasing an additional 46 shares in the last quarter. Banque Transatlantique SA purchased a new position in Cencora during the 4th quarter worth approximately $29,000. SBI Securities Co. Ltd. purchased a new position in Cencora during the 4th quarter worth approximately $30,000. Kentucky Trust Co purchased a new position in Cencora during the 4th quarter worth approximately $33,000. Finally, WASHINGTON TRUST Co grew its position in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after purchasing an additional 46 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Performance

COR stock opened at $290.03 on Friday. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market capitalization of $56.21 billion, a price-to-earnings ratio of 41.26, a P/E/G ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $309.35. The firm has a 50 day moving average of $281.86 and a two-hundred day moving average of $256.65.

Cencora (NYSE:COR – Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.80 earnings per share. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend is Friday, May 16th. Cencora’s dividend payout ratio is 25.52%.

Analyst Upgrades and Downgrades

COR has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Evercore ISI boosted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. UBS Group boosted their price objective on shares of Cencora from $298.00 to $335.00 and gave the company a “buy” rating in a research report on Tuesday, April 29th. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Finally, Citigroup boosted their price objective on shares of Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $301.18.

Read Our Latest Analysis on Cencora

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 14,579 shares of the company’s stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares of the company’s stock, valued at approximately $89,027,442.53. This represents a 4.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the sale, the chief executive officer now directly owns 51,070 shares of the company’s stock, valued at approximately $13,022,850. This represents a 8.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,223 shares of company stock valued at $12,369,767 over the last ninety days. Corporate insiders own 10.80% of the company’s stock.

About Cencora

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Recommended Stories

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).